Key result
Nonsteroidal MRAs and novel aldosterone synthase inhibitors offer cardiovascular and renal benefits in primary aldosteronism.
Design
Review
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for nonsteroidal MRAs and ASI in primary aldosteronism; leaves open adoption pending dedicated randomized trials.
Yoshida et al. (2026) studied this question. Nonsteroidal mineralocorticoid receptor antagonists and novel aldosterone synthase inhibitors offer improved cardiovascular and renal benefits for patients with primary aldosteronism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: